vanoxerine has been researched along with Cerebral Ischemia in 1 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maginn, M | 1 |
| Kelly, JP | 1 |
| Leonard, BE | 1 |
1 other study available for vanoxerine and Cerebral Ischemia
| Article | Year |
|---|---|
Protective effects of vanoxeamine (GBR 12909) against ischaemia-induced hyperactivity and neurodegeneration in the gerbil model of cerebral ischaemia.
Topics: Animals; Brain Ischemia; Cell Death; Dopamine; Dopamine Uptake Inhibitors; Gerbillinae; Hippocampus; | 1997 |